Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly stock is surging after the pharma giant beat Q2 estimates and lifted its full-year outlook. Here's what you need to know.

Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter

Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics

Eli Lilly And Co   (NYSE:LLY) surpassed top- and bottom-line expectations for the second quarter, and lifted its full-year revenue outlook by $3 billion amid strong sales of weight loss drug and diabetes drugs Zepbound and Mounjaro.

Options Bulls Target Eli Lilly Stock After Beat-and-Raise

Morphic Holding Inc

NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!

Eli Lilly (NYSE: LLY ) stock rose 13% overnight after it beat analyst estimates and raised guidance. The company's GLP-1 drugs for diabetes and weight loss, Zepbound and Mounjaro, propelled the results.

LLY Stock Alert: Why Are Eli Lilly Shares Surging Today?

Eli Lilly (LLY) came out with quarterly earnings of $3.92 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.11 per share a year ago.

Eli Lilly (LLY) Surpasses Q2 Earnings and Revenue Estimates

Eli Lilly (LLY) shares surged higher in premarket trading Thursday after the drugmaker's second-quarter earnings came in well above analysts' estimates and it raised its full-year revenue and profit guidance.

Eli Lilly Stock Soars as Mounjaro, Zepbound Power Earnings Beat, Guidance Boost

8.30am: Wall Street to open flat US markets are set to open flat today, with stocks struggling to stabilise as recession fears were renewed and carry trades continued to unwind.  The Dow Jones is shifting slightly lower in premarket futures, predicted to open 46 points lower at 38,864.

Nasdaq and S&P 500 to open flat as recession fears grow; Eli Lilly rallies

Pharma titan Eli Lilly on Thursday reported strong demand for its weight loss and diabetes drugs Zepbound and Mounjaro, smashing analysts' expectations in the face of growing competition in the lucrative weight loss drug market as it struggles to boost supplies and tackle shortages.

Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales Soar

Eli Lilly reports Q2 EPS of $3.92, exceeding expectations. Revenue reaches $11.30 billion, driven by strong drug sales.

Blockbuster Drugs Drive Eli Lilly's Strong Q2 Performance

Eli Lilly earnings easily beat amid booming sales of weight-loss drug Zepbound and diabetes fighter Mounjaro. The drug giant raised guidance.

Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound, Mounjaro Sales Boom

Eli Lilly reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound spike. The drugmaker now expects full-year adjusted earnings of $16.10 to $16.60, up from a previous guidance of $13.50 to $14 per share.

Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar

Shares of Eli Lilly & Co. LLY, -2.65% shot up 8.5% in premarket trading Thursday, after the drug maker reported second-quarter earnings that rose well above forecasts, boosted by strength in its diabetes and obesity treatments, Mounjaro and Zepbound and by higher prices. Net income jumped to $2.97 billion, or $3.28 a share, from $1.76 billion, or $1.95 a share, in the same period a year ago.

Eli Lilly's stock leaps after big earnings beat, boosted by strength in Mounjaro and Zepbound sales

Eli Lilly on Thursday raised its annual profit forecast and sales of its popular weight-loss drug Zepbound crossed $1 billion for the first time in a quarter.

Eli Lilly raises annual profit forecast as Zepbound quarterly sales cross $1 billion

Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%.

Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion

MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Defiance ETFs proudly unveils LLYX, the world's first single-stock leveraged ETF for Eli Lilly. LLYX offers retail investors 2X daily long leveraged exposure to the change in the daily share price of Eli Lilly without the need for a margin account, providing a unique tool for tactical traders.

Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly

A rival pharmaceutical company released promising clinical trial results from a weight-loss treatment. Eli Lilly is one of two companies dominating the obesity drug market right now.

Here's Why Eli Lilly Stock Dropped 12% Last Month

Investors will be looking for updates on Zepbound's rollout, and projections for when supply shortages in the U.S. might end.

Eli Lilly Reports Earnings Thursday Amid a Stock Slump

Eli Lilly and Co LLY will be reporting its second-quarter earnings on Thursday. Wall Street expects $2.70 in EPS and $9.9 billion in revenues as the company reports before market hours.

Eli Lilly: Bearish Signals Loom Over Weight Loss Stock Ahead Of Q2 Earnings

NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!

Eli Lilly and Company LLY is expected to release earnings results for its second quarter, before the opening bell on Thursday, Aug. 8.

How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings

Novo Nordisk

Given their underperformance in 2024, a positive set of quarterly results could easily push both stocks higher.

Eli Lilly (LLY) & Novo Nordisk (NVO) Earnings: A Closer Look

Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.

Can Mounjaro & Zepbound Drive Eli Lilly (LLY) Q2 Earnings?

Eli Lilly stock (NYSE: LLY) will report its Q2 results on Thursday, August 8. The pharmaceutical giant is expected to garner $10 billion in sales and $2.70 in adjusted earnings per share, per the consensus estimates.

Will The Supply Shortage Weigh On Eli Lilly's Q2?

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!

News for Eli Lilly Stock (LLY)